Infectious Diseases

Geneva’s accomplished team of experts has made significant advancements in the development of novel therapeutics, rapid diagnostics, effective countermeasures, and successful treatments for some of the world’s most devastating global health threats.

Geneva collaborates on infectious diseases research at federal laboratories and military treatment facilities including: U.S. Army Medical Research Institute for Infectious Diseases, Walter Reed Army Institute of Research, and Armed Forces Research Institute of Medical Sciences.

PERFORMANCE CAPABILITIES

Geneva research teams and collaborators have vast experience in the following areas:

  • Access to BSL-3 and BSL-4 laboratories for vector borne research
  • Antigen vaccine discovery and development
  • Adjuvant vaccine formulation and delivery
  • Biosurveillance efforts
  • Basic science discovery
  • Biomarker diagnostics
  • Development of antibody-based therapeutics
  • Development of diagnostics and therapeutics
  • Global health initiatives
  • Pre-clinical optimization and efficacy

Geneva Expertise

FEATURED PROGRAM
Operation Warp Speed

Geneva supports Operation Warp Speed at military treatment facilities across the U.S. to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

 
Featured Researcher
Andrew Herbert, PhD

Dr. Herbert is part of the Prometheus Group, an international consortium of investigators working on developing monoclonal antibody therapies for some of the world’s most deadly infectious diseases, including COVID-19.

 
Researcher of the Year
John Dye, PhD

Dr. Dye, Chief of Viral Immunology at USAMRIID, oversees the execution of the Army’s research programs aiming to counteract the Ebola virus and other high-risk pathogens that threaten global health.

 

Case Study: Operation Warp Speed

When the federal government unveiled Operation Warp Speed (OWS) in May 2020, it was “unlike anything our country has seen since the Manhattan Project.” The multi-agency initiative’s central goal – to develop, produce, and distribute 300 million doses of a safe and effective coronavirus vaccine by January 2021 – requires a deep knowledge of science and how to manage complex government operations while navigating a challenging pandemic.

Geneva responded to the opportunity of a lifetime to join the fight against COVID-19. In August 2020, prime contract research organization (CRO) Pharm-Olam and Geneva were selected by the U.S. Department of Defense (DoD) to support Phase 3 clinical trials for one or more vaccine candidates.

GENEVA’S ROLES

• Clinical Trials Management at Military Treatment Facilities (MTFs)
• Regulatory Expertise
• Scientific Expertise
• Recruitment of Highly Skilled Medical and Technical Personnel

Today, Geneva employs 116 employees across the U.S. supporting OWS with 1,720 total participants enrolled across six military treatment facilities nationwide.

Research Indications

Geneva has diverse experience in managing Category A, B, and C priority pathogens and infectious diseases programs in indications including:

Andes Virus
Anthrax
Arenavirus Botulism
Bunyavirus
Chikungunya virus
Coronavirus
Crimean Congo
E.coli
Eastern equine encephalitis
Flavivirus
Hemorrhagic Fever
Dengue Fever
Ebola
Filovirus
Glanders
Hantavirus
Junin virus
Lassa virus
Malaria
Marburg virus
Melioidosis
Plague
Ricinus communis
Rift Valley Fever
Salmonella
Smallpox
Tulamia
Venezuelan equine encephalitis
West Nile virus
Western equine encephalitis
Zika virus